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Abstract
The clinical goals of risk stratification of sudden death are to identify subjects who are at high
risk of, and eventually to reduce the incidence of, sudden death. Numerous studies have
described risk stratification techniques for serious cardiac events in patients following myocar-
dial infarction. However, relatively little information is available regarding nonischemic di-
lated cardiomyopathy. A number of diagnostic methods have been used for risk stratification of
patients with nonischemic dilated cardiomyopathy, including presence of syncope, ambulatory
electrocardiographic monitoring, programmed ventricular stimulation, QRS duration, QT
interval dispersion, QT interval dynamicity, signal-averaged ECG, heart rate variability,
heart rate turbulence, baroreflex sensitivity, heart rate recovery, exercise recovery ventricular
ectopy, fragmented QRS and cardiac magnetic resonance imaging. In this review, existing
data regarding risk stratification of sudden cardiac death in nonischemic dilated cardiomyo-
pathy will be summarized and its implications in clinical practice will be reviewed. (Cardiol J
2010; 17, 3: 219–229)
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Introduction
Nonischemic dilated cardiomyopathy (NIDCM)
is a primary disease of the myocardium, characteri-
zed by left or biventricular dilatation and systolic
contractile dysfunction. The incidence of NIDCM
is five to eight cases per 100,000 population per year
[1, 2]. Approximately half of patients with recently
diagnosed NIDCM die within the first year [3]. Af-
fected patients have impaired systolic function and
may develop heart failure (HF). The presenting
manifestations may include lethal arrhythmias and
sudden cardiac death (SCD) which could occur at
any stage of the disease. The majority of SCDs oc-
cur in patients who are defined as low risk, includ-
ing patients with New York Heart Association
(NYHA) functional class I or II. The incidence of
SCD in NYHA class IV HF is also high, but the risk
of HF makes SCD the second cause of death in this
category of patients [4, 5].
With the advent of implantable cardioverter
defibrillators (ICDs), it is now possible to prevent
SCD. However, the critical issue is to identify the
patients who benefit the most. In order to balance
the potential risks of device implantation with the
associated cost, many investigators have tried to
establish risk stratifications. Risk stratification
should particularly involve a process of distinguish-
ing subjects at relatively high risk of future major
events.
A number of diagnostic methods have been
used for risk stratification of patients with NIDCM,
including presence of syncope, ambulatory electro-
cardiographic monitoring, programmed ventricular
stimulation, QRS duration, QT interval dispersion,
QT interval dynamicity, signal-averaged ECG,
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heart rate variability, heart rate turbulence,
baroreflex sensitivity, heart rate recovery, recove-
ry ventricular ectopy, fragmented QRS and car-
diac magnetic resonance imaging [4]. However,
effective and clinically useful risk stratification in
NIDCM patients remains a challenge. Low ejection
fraction and advanced NYHA functional class are
proven important risk factors. However, the high
sensitivity of these parameters means less speci-
ficity. Moreover, preserved left ventricular function
is increasingly seen in HF patients, and there is
very limited data regarding risk stratification in that
population [6]. The purpose of this review is to sum-
marize the risk stratification methods of SCD in
NIDCM and to look at the implications of these
methods in clinical practice.
Syncope
In several clinical studies, patients with NIDCM
who experienced syncope have been shown to be
at high risk of sudden death [7]. In comparison to
patients without documented ventricular tachycar-
dia (VT)/ventricular fibrillation (VF) but with a his-
tory of unexplained syncope, patients who have
survived documented cardiac arrest reveal similar
mortality [8]. In one particular study, Middlekauff
et al. [9] reported a one-year actuarial SCD risk of
45% in patients with advanced HF (51% due to
NIDCM) and syncope, versus 12% in patients with
advanced HF who had not experienced syncope.
Brembilla-Perrot et al. [10] described a high preva-
lence (70%) of previous syncopal events in NIDCM
patients with SCD over a mean follow-up duration
of two years. Most of the mortality associated with
NIDCM and syncope can be attributed to sudden car-
diac death. In another study, Fruhwald et al. [11] found
a large proportion (83%) of deaths in patients with
NIDCM and syncope were characterized as SCD.
The diagnostic value of electrophysiological
testing is limited in predicting SCD in patients with
NIDCM and syncope. Data on ICD implantation in
the population of patients with NIDCM and synco-
pe is limited to smaller, uncontrolled observational
clinical studies. Knight et al. [8] published a pro-
spective analysis of 14 patients with NIDCM and
unexplained syncope who underwent ICD implan-
tation versus a comparator group of 19 survivors of
SCD with NIDCM. They reported a high incidence
(50%) of appropriate defibrillator shocks in the
NIDCM patients with syncope. This was compara-
ble to the rate of corresponding events (42%) in
those who had survived cardiac arrest. Further-
more, there was no significant difference in mor-
tality (28% in those with syncope and 32% in SCD
survivors) between the two groups.
In one recent study, Phang et al. [12] compared
108 consecutive patients with NIDCM presenting
with syncope to 71 patients with NIDCM who pre-
sented with sustained ventricular arrhythmias, with
regard to freedom from any ventricular arrhythmias
or life-threatening arrhythmias and all-cause mor-
tality. In this large group of patients with NIDCM
presenting with syncope, they found that such pa-
tients were at high risk of ventricular arrhythmias
and mortality, as high as patients with NIDCM pre-
senting with sustained ventricular arrhythmias.
Based on the available scientific evidence in
patients with NIDCM, American College of Cardio-
logy (ACC)/American Heart Association (AHA)/
/Heart Rhythm Society (HRS) 2008 Guidelines for
Device-Based Therapy of Cardiac Rhythm Abnorma-
lities [13] recommends ICD implantation as reason-
able for patients with unexplained syncope, significant
left ventricular (LV) dysfunction, and NIDCM.
Ambulatory electrocardiographic
monitoring
The value of detection of asymptomatic ventri-
cular arrhythmias in patients with systolic ventricu-
lar dysfunction is controversial. Many HF specialists
specifically do not recommend performing ambulato-
ry electrocardiography (AECG) monitoring in patients
without symptoms of palpitations or syncope. This
advice is derived from the numerous antiarrhythmic
trials that showed increased mortality using class IA,
class IC, and class III antiarrhythmic agents [14, 15].
The incidence of non-sustained ventricular ta-
chycardia (NSVT) in patients with NIDCM varies
from 33–79% [16, 17]. The prognostic significance
of NSVT in AECG monitoring in patients with
NIDCM has been previously explored in relatively
small observational studies. Meinertz et al. [18] (in
74 patients with NIDCM) and Unverferth et al. [19]
(in 69 patients with NIDCM) found a significant as-
sociation between the presence of ventricular ar-
rhythmias detected on AECG and the risk of mor-
tality in patients with NIDCM. In contrast, von
Olshausen et al. [20] (in 73 patients with NIDCM)
and Costanzo-Nordin et al. [21] reported that the
presence of NSVT on AECG did not predict poor
clinical outcome in patients with NIDCM. Iacoviel-
lo et al. [22] recently reported that detection of
NSVT on AECG significantly improved risk strati-
fication in 179 consecutive NIDCM patients.
Baker et al. [23] recently assessed a cohort of
144 patients with NIDCM. Non-sustained ventri-
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cular tachycardia was found in 31% of patients dur-
ing AECG monitoring. Age, low ejection fraction,
higher mean heart rate, lower heart rate range, and
presence of NSVT were found as predictors of mor-
tality. In another study, Grimm et al. [24] assessed
a cohort of 343 patients with NIDCM using multi-
ple diagnostic tests to assess risk for SCD. The
presence of NSVT on AECG was associated with
a trend towards an increased risk of major arrhyth-
mic events without statistical significance. Grimm
et al. [25] examined the prognostic significance of
the rate and length of NSVT on AECG recorded in
same cohort of 343 patients with NIDCM. NSVT
was defined as ≥ three consecutive ventricular pre-
mature beats at > 120 bpm. Patients with 3–4 beat
runs of NSVT had arrhythmia-free survival compa-
rable to patients without NSVT on AECG. The in-
cidence of major arrhythmic events during follow-
up was 2% in patients without NSVT, 5% in patients
with 5–9 beat runs of NSVT and 10% in patients
with ≥ ten beat runs of NSVT. Unlike the length,
the rate of NSVT was similar in patients with ver-
sus without subsequent major arrhythmic events
(163 ± 23 vs 160 ± 24 bpm). Therefore, the length,
but not the rate, of NSVT on AECG was found as
a predictor of major arrhythmic events in patients
with NIDCM.
Despite the fact that we have evidence from
several studies, the prognostic importance of NSVT
or frequent ventricular arrhythmias has not fully
been understood. Clinical studies have shown that
NSVT is predominantly a marker of risk for cardiac
mortality but is not very efficient in selecting a high
risk group for SCD.
Programmed ventricular stimulation
Programmed ventricular stimulation (PVS) has
been useful for risk stratification in patients with
coronary artery disease (CAD), but its utility in pa-
tients with NIDCM has been controversial. Utili-
zation of PVS in NIDCM has been studied in rather
small and inhomogeneous groups [26]. The com-
monest finding of PVS in patients with NIDCM is
polymorphic VT or VF which is a non-specific ar-
rhythmia [27]. In addition, the variability of stimula-
tion protocols makes assessment of predictive va-
lues difficult. For instance, in the studies of Stamato
et al. [28] and Hammill et al. [29], there was no in-
ducible sustained polymorphic VT or VF. In contrast,
Grimm et al. [30] reported the incidence of induci-
ble sustained polymorphic VT or VF as 29%. This
discrepancy might reflect differences in patient se-
lection and stimulation protocol.
Grimm et al. [30] assessed the role of PVS for
arrhythmia risk prediction in 34 patients with
NIDCM and spontaneous NSVT. Arrhythmic events
occurred in 31% of patients with inducible sustained
ventricular arrhythmias, compared to 24% of pa-
tients without inducible sustained ventricular ar-
rhythmias at PVS, but there was no statistically sig-
nificant difference. Inducibility of sustained mono-
morphic VT as well as inducibility of polymorphic
VT or VF at PVS failed to predict subsequent ar-
rhythmic events. Becker et al. [26] investigated the
prognostic role of asymptomatic NSVT and PVS in
99 patients with NIDCM. They suggested that PVS
was inappropriate to specifically identify patients at
high risk of SCD because of a low inducibility rate
(7%) and a relatively poor positive predictive value
for subsequent arrhythmic events (29%).
QRS duration
QRS duration is a simple measure of the dura-
tion of ventricular activation measured on the 12-lead
ECG and is a manifestation of intraventricular or
interventricular conduction delay. Prolongation of
QRS (120 ms) on 12-lead electrocardiogram occurs
in 14–47% of patients with HF [31]. Left bundle
branch block (BBB) is far more common than right
BBB. Left-sided intraventricular conduction delay
is associated with more advanced myocardial dis-
ease, worse left ventricular (LV) function, poorer
prognosis, and a higher all-cause mortality rate com-
pared to narrow QRS complex. Baldasseroni et al.
[32] demonstrated that NYHA class III–IV HF pa-
tients with QRS prolongation (left BBB) have an in-
creased mortality at one year. Silverman et al. [33]
investigated the impact of the etiology of HF on the
prognostic importance of a prolonged QRS and an
abnormal SAECG in 200 patients with HF. Patients
were categorized according to etiology of HF and
electrocardiographic parameters. The mortality of
patients with a prolonged QRS was comparedto the
mortality in those with both abnormal and normal
SAECGs. NIDCM patients with a prolonged QRS
had significantly worse survival than other patients.
However, nonischemic patients with an abnormal
SAECG did not have a worse prognosis than pa-
tients with a normal SAECG. In contrast, a pro-
longed QRS was not a predictor of poor prognosis in
patients with ischemic cardiomyopathy [33].
The Sudden Cardiac Death in Heart Failure
Trial (SCD-HeFT) was a randomized, placebo-con-
trolled study designed to determine whether ami-
odarone or a single-chamber ICD programmed to
shock only would reduce all-cause mortality when
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compared to a placebo in patients with dilated cardio-
myopathy (ischemic or nonischemic), NYHA func-
tional class II and III HF, and LV dysfunction (LVEF
35%) [34]. A total of 2,521 patients were enrolled
with randomization to ICD (n = 829), amiodarone
therapy (n = 845), or placebo (n = 847). The medi-
an age of patients was 60 years (range 19–90). Both
ischemic and nonischemic patient groups were found
to benefit from ICD therapy. When stratifying the
ECG data in the ICD versus placebo groups, ICD
therapy was associated with a significant reduction
in the risk of mortality comparedto placebo, regard-
less of the ECG measure, including QRS duration
< 120 ms or 120 ms. Another analysis found that al-
though ICD shock rates were highest in patients with
a longer QRS duration, patients with a narrow QRS
also experienced a significant number of shocks,
suggesting that treatment is warranted for this group
[34]. Dhar et al. [35] evaluated the prognostic sig-
nificance of QRS duration for arrhythmic outcomes
in 1,232 patients who were enrolled in the Multi-
center Automatic Defibrillator Implantation Trial
(MADIT) II. Patients were randomized to ICD im-
plant plus conventional medical therapy versus con-
ventional medical therapy alone, in a 3:2 ratio. In the
medically-treated arm, the 138 patients (29%) with
QRS duration ≥ 140 ms exhibited more than a dou-
bled risk of SCD. However, in the ICD-treated arm,
the 255 patients (35%) with QRS duration ≥ 140 ms
showed no difference in time to SCD or first appro-
priate ICD therapy for rapid VT/VF compared to
those with QRS duration < 140 ms.
In contrast to the studies presented above, in
the Marburg Cardiomyopathy Study, Grimm et al.
[24] reported no significant correlation between
intraventricular conduction delay and SCD during
the follow-up. In the Defibrillators in Non-Ische-
mic Cardiomyopathy Treatment Evaluation (DEFI-
NITE) study, 458 NIDCM patients with a left ven-
tricular ejection fraction (LVEF) of £ 35%, and pre-
mature ventricular complexes or NSVT were en-
rolled. There was no significant association between
QRS duration and all-cause mortality [36].
Although the data is not uniform, a moderate
amount of data showed that increased QRS duration
identifies patients at higher risk of SCD. Prospec-
tive trials specifically designed to address this issue
are needed for the use of QRS duration to further
stratify risk for SCD in patients with NIDCM.
QT dispersion and QT interval dynamicity
Ventricular repolarization is a critical time in
the cardiac cycle, playing a considerable role in the
pathophysiology of malignant arrhythmias. Twelve-
-lead ECG measurements of the QT interval (i.e. QT
interval and QTd) are considered a global index of
the duration. Dispersion of repolarization in the
ventricular myocardium has largely been investi-
gated in order to better identify patients with vari-
ous clinical conditions prone to experience major
arrhythmic events [22, 37]. It has been reported that
an increased QT dispersion is associated with ar-
rhythmic events in various clinical settings, such
as long QT syndrome, HF, coronary artery disease,
post-myocardial infarction or hypertrophic cardio-
myopathy [37]. However, the ability of QT disper-
sion (QTd) to identify cardiac patients at high risk
of sudden death remains uncertain due to conflict-
ing findings. This could be due to the fact that ECG
parameters poorly reflect the complexity of the
ventricular repolarization process depending on
different dynamic components as transmembrane
ion currents, heart rate, and autonomic nervous
system activity [22].
Galinier et al. [38] reported that QTd was sig-
nificantly higher in NIDCM patients with SCD. In
multivariate analysis, only a QTd > 80 ms was an
independent predictor of sudden death and arrhyth-
mic events in NIDCM, but not in ischemic heart
disease. Fei et al. [39] found, in 60 patients with
NIDCM, that there was no significant difference in
QTd between survivors and those who died or were
transplanted during follow-up. Furthermore, no sig-
nificant difference in QTd was observed between
patients with and without VT detected on AECG.
Grimm et al. [40] investigated QTd in 107 patients
with NIDCM compared to 100 healthy matched
controls. The usefulness of QTd for risk stratifica-
tion was limited due to the large overlap of QTd
among patients with and without arrhythmic events
during a follow-up of 13 ± 7 months. Grimm et al.
[24] also found negative results with QTc disper-
sion with a longer follow-up in 343 patients with
NIDCM in the Marburg Cardiomyopathy Study.
Fauchier et al. [41] recently assessed the role of
QTd for the long-term risk of cardiac death and of
major arrhythmic events in 162 NIDCM patients.
They reported that QT dispersion was not a pre-
dictor of cardiac death in univariate or in multiva-
riate analysis, and was of similar value for patients
with or without bundle branch block.
QT dynamicity is the one of the novel meth-
ods that could be used in risk stratification of SCD.
The QT dynamicity indices considered in the studies
were: the QT-slope (the slope of the regression line
between QT and RR during the 24-hour period) and
the mean QT corrected for heart rate (Bazett’s
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formula). Iacoviello et al. [22] assessed the QT in-
terval dynamicity in 179 consecutive NIDCM pa-
tients without a history of sustained VT and/or
VF at enrollment. During a mean follow-up of
39 months, nine patients died suddenly and 15 ex-
perienced VT and/or VF. At multivariate analysis,
LVEF, NSVT and QTe-slope were significantly as-
sociated with arrhythmic events. Increased QTe-
-slope in patients with NIDCM was associated with
the occurrence of major arrhythmic events regard-
less of other clinical variables, suggesting its clini-
cal usefulness in stratifying arrhythmic risk. The
limitations of QT/RR slope analysis are strictly re-
lated to the feasibility of measuring. Patients with
atrial fibrillation or paced rhythm, as well as those
with abnormal ventricular repolarization, could not
be optimally evaluated [22].
Signal averaged ECG
Signal-averaged ECG is used to detect the oc-
currence of late activation within the myocardium (late
potentials) noninvasively by means of surface ECG
electrodes. As the late potentials are small in ampli-
tude (in the microvolt range), the only way to obtain
an acceptable signal-to-noise ratio from the body sur-
face is to average together hundreds of QRS complex-
es to determine a mean QRS morphology [42].
Typically, three parameters are assessed in
SAECG: the duration of the filtered QRS (fQRS)
complex, the duration of any low-amplitude signal
(LAS; signal, < 40 mV), and the root-mean-square
(RMS) voltage in the last 40 ms of the QRS. Many
investigators consider the SAECG to be ‘abnormal’
if any two of these three parameters are abnormal.
The normal values for SAECG are instrument-spe-
cific and dependent on gender [43]. SAECG appears
to be useful in arrhythmia risk stratification of pa-
tients with ischemic heart disease. Most of the stud-
ies concerning the prognostic value of SAECG in
homogenous populations with NIDCM gave con-
flicting results [44].
Mancini et al. [45] found abnormal SAECG as
a predictor of death and/or VT in 114 patients with
NIDCM who referred for heart transplantation. Al-
though the results of this study in high-risk patients
were promising, the prognostic value of SAECG
remained unknown because there have been no
large studies in mildly symptomatic patients with
NIDCM. Another important point in this study was
the inclusion of individuals with BBB, which com-
promises the utility of the SAECG as an adequate
method for risk stratification in this population. In
the first year of follow-up, survival was 95% in pa-
tients with a normal SAECG, 88% in patients with
a BBB, and only 39% in patients with an abnormal
SAECG [45]. Fauchier et al. [44] evaluated the long-
term prognostic value of SAECG in 131 patients
with NIDCM. Late potentials on SAECG were
present in 27% of the patients. Patients with late
potentials had an increased risk of all-cause cardi-
ac death and of arrhythmic events.
In contrast, Silverman et al. [33] found that an
abnormal SAECG was an independent predictor of
all-cause death in patients with HF due to ischemia,
whereas this was not the case in patients classified
as having NIDCM. On the other hand, Turitto et al.
[46] found that the two-year actuarial survival free
of arrhythmic events was similar in patients with
or without abnormal findings on SAECG. Galinier
et al. [47] prospectively followed 151 patients with
HF, 48% of whom were diagnosed with NIDCM. At
baseline, late potentials were detected in 34% of the
NIDCM patients, which was similar to the incidence
of late potentials in patients with HF due to CAD.
Late potentials were not found to be predictive of
total mortality or sudden cardiac death. In the Mar-
burg Cardiomyopathy Study, Grimm et al. [24] per-
formed arrhythmia risk stratification in 343 patients
with NIDCM, including analysis of LVEF and size
by echocardiography, SAECG, AECG, QTc disper-
sion, heart rate variability, baroreflex sensitivity,
and microvolt T-wave alternans (TWA). SAECG,
baroreflex sensitivity, heart rate variability, and
TWA were not found to be useful for arrhythmia risk
stratification.
Based on the data presented above, an abnor-
mal result on SAECG might be a marker of in-
creased risk of sustained ventricular tachycardia or
death. SAECG appears to have a superior negative
predictive value, with the caution that the presence
of bundle branch block may significantly lower the
specificity of SAECG. However, the poor positive
predictive value for arrhythmic events and de-
creased specificity in the significant number of pa-
tients with bundle branch block reduces the value
of this test.
T wave alternans
TWA is an ECG phenomenon defined as beat-
to-beat alternation of the morphology, amplitude,
and/or polarity of the T-wave. It refers to alterna-
tion of the electrocardiographic ST-segment, T- and
U-wave. The use of TWA relies upon microvolt lev-
el fluctuations that are invisible to the naked eye
but require computerized signal processing meth-
ods to be demonstrated.
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Adachi et al. [48] evaluated TWA as a predic-
tor of arrhythmic events and sudden cardiac death
in 82 patients with NIDCM. During an average fol-
low-up duration of 24 months, ten patients experi-
enced arrhythmic events. Nine of them had a posi-
tive TWA; the negative and positive predictive val-
ues of TWA were found to be, respectively, 97%
and 30%, whereas the relative risk was 10.2.
Kitamura et al. [3] studied 104 patients with
NIDCM with the goal of assessing whether the
heart rate threshold at which TWA appears (onset
heart rate) would be of prognostic value. Onset of
TWA with heart rates below 100/minute conferred
increased risk of SCD or sustained VT/VF, with
a predictive accuracy of 78%. Hohnloser et al. [49]
assessed the predictive value of TWA and of conven-
tional risk stratifiers in 137 patients with NIDCM.
Arrhythmic events occurred in 13 patients who
were positive, two who were negative, and three
who were indeterminate for TWA. At multivariate
analysis, TWA was the only independent predictor
of an arrhythmic event, whereas LVEF, heart rate
variability (HRV), and the presence of NSVT did not
show a significant predictive value. In the multi-
center study by Bloomfield et al. [50] NIDCM was
present in 282 patients (51%). The two-year event
rates for the primary end point (all-cause mortality
or non-fatal VT) were 13.3% and 0% respectively
among patients with abnormal and normal TWA tests.
In contrast to these positive findings, Grimm
et al. [24] did not find TWA to predict the risk of
arrhythmias in a population of 343 patients with
NIDCM, of whom 263 were in sinus rhythm and
underwent the analysis. On multivariate analysis,
only reduced LVEF proved to be a significant pre-
dictor of arrhythmic events, whereas TWA, HRV,
baroreceptor sensitivity (BRS), and the presence of
late potentials had no additional value.
The T-wave Alternans in Patients with Heart
failure (ALPHA) study evaluated the independent
predictive value of TWA in 446 patients with NIDCM
[51]. Patients with a history of cardiac arrest or
sustained VT were excluded. The primary end point
of the study was the combination of cardiac death
and life-threatening arrhythmias; the secondary end
points were total mortality and the combination of
arrhythmic death and life-threatening arrhythmias.
Enrolled patients were followed up for 18 to
24 months (median time 19 months); during this fol-
low-up, 28 patients died (18 of cardiac causes and
seven of sudden death) and 11 patients had symp-
tomatic sustained VT or VF. The TWA test was
negative in 34.6% of the patients, positive in 44.8%,
and indeterminate in 20.6%. Primary end point rates
in patients with abnormal and normal TWA tests
were 6.5% (95% confidence interval [CI]: 4.5–9.4%)
and 1.6% (95% CI: 0.6–4.4%), respectively. The
study concluded that patients with a normal TWA
test have a very good prognosis and are likely to
benefit little from ICD therapy [51]. Also in a re-
cent meta-analysis, De Ferrari et al. [52] evaluated
1,456 NIDCM patients and reported that abnormal
(both positive and indeterminate) TWA patients
have a three times greater risk compared to nor-
mal TWA patients. Despite these significant results,
which points to TWA as the most effective risk
stratifier in this population of patients, the positive
predictive value of the test remains relatively low.
The ACC/AHA/ESC 2006 Guidelines for Mana-
gement of Patients with Ventricular Arrhythmias
and the Prevention of Sudden Cardiac Death rec-
ommends the use of TWA as reasonable to improve
the diagnosis and risk stratification of patients with
ventricular arrhythmias or who are at risk of deve-
loping life-threatening ventricular arrhythmias
(Class II, Level of Evidence: A) [5].
Heart rate variability
Measures of autonomic function have been
evaluated to estimate risk for SCD. Heart rate vari-
ability is an indirect measure of cardiac autonomic
activity, which is the evaluation of beat to beat vari-
ability of the R-R interval. Required data is obtained
from digitized AECG tracings. HRV can be analyzed
in the time domain or in the frequency domain [42].
Common time-domain measures of HRV include
the following: SDNN, the standard deviation (SD)
of the R-R interval; SDANN, the SD of the five-
-minute mean R-R intervals tabulated over an en-
tire day and the SD index; and the mean of the five-
minute SDs of the R-R interval tabulated over the
entire day. Frequency domain measures of HRV are
usually classified according to the following range
of frequencies analyzed: ultra-low frequency (ULF;
< 0.0033 Hz); very low frequency (VLF; 0.0033–
–0.04 Hz); low frequency (LF; 0.04–0.15 Hz); high
frequency (HF; 0.15–0.40 Hz) or total power [42].
Previous studies have proven that HRV is pre-
dictive of arrhythmic occurrences following myo-
cardial infarction [5]. Observational studies also
suggest that it may be useful in the presence of
NIDCM [5]. Fauchier et al. [53] found a weak to
moderate correlation between SDNN and left ven-
tricular function in 93 patients with dilated NIDCM.
On multivariate analysis, these investigators iden-
tified SDNN as an independent predictor of cardiac
death or heart transplant. Yi et al. [54] also showed
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that reduced heart rate variability had independent
predictive value for death from progressive HF in
a cohort of 64 patients with dilated cardiomyopa-
thy. In a large prospective multicenter study, No-
lan et al. [55] investigated the prognostic value of
heart rate variability in 433 outpatients with HF. In
that study, SDNN was associated with death from
progressive HF, but not with sudden cardiac death.
In the DEFINITE (Defibrillators in Non-ischemic
Cardiomyopathy Treatment Evaluation) trial, Rash-
ba et al. [56] showed that patients with NIDCM and
preserved HRV have an excellent prognosis and
may not benefit from prophylactic ICD placement.
These results appear to contradict those of Grimm
et al. [24], where findings did not support the use
of HRV to select patients with NIDCM for prophy-
lactic ICD therapy.
Based on the data presented above, patients
with NIDCM have decreased heart rate variability.
However, this decrease is associated with systolic
ventricular function, and does not correlate with
increased risk of ventricular arrhythmias. The
weight of the evidence suggests that due to the poor
positive predictive value of HRV, this test has lit-
tle role to play in risk stratification for sudden death
of patients with NIDCM.
Heart rate turbulence
Following a ventricular premature complex
(VPC) with a compensatory pause, there is known
to be an initial acceleration, and a later decelera-
tion, of sinus rhythm. This sequence is termed heart
rate turbulence (HRT), and it is thought to be
a measure of the autonomic response to perturba-
tions of arterial blood pressure invoked by a VPC
[57]. HRT parameters included turbulence onset
(TO) and turbulence slope (TS). TO was calculated
as the percentage change between the mean of the
first two sinus RR intervals after a VPC and the last
two sinus rhythm RR intervals before the VPC.
These measurements were performed for each sin-
gle VPC and subsequently averaged. The TS was
calculated as the maximum positive slope of a re-
gression line assessed over any sequence of five
subsequent RR intervals within the tachogram [57].
Grimm et al. [58] investigated the prognostic
significance of HRT in 242 NIDCM patients who
were enrolled in the Marburg Cardiomyopathy da-
tabase. In this study, HRT onset was found as a sig-
nificant predictor of transplant-free survival, in the
same way as LV size and NYHA class. However, only
LVEF remained a significant risk predictor on mul-
tivariate analysis for arrhythmia risk stratification.
In the Muerte Subita e Insuficiercia Cardiaca
(MUSIC; Sudden Death in Heart Failure) study,
576 patients with HF and sinus rhythm enrolled in
a study designed to assess risk predictors of sudden
cardiac death in patients with HF in NYHA classes
II and III [59]. Both HRT parameters, but especial-
ly turbulence slope, were significantly correlated
with clinical indices of HF (the third heart sound,
peripheral edemas, jugular distension, and pulmo-
nary congestion). Patients in NYHA class III had
significantly lower turbulence slopes and greater
turbulence onset values than those in class II. Abnor-
mal HRT parameters were associated with longer
QRS duration, higher mean heart rate, more frequent
ventricular arrhythmias and progressively decreasing
parameters of heart rate variability. Abnormal HRT
parameters were found as independent predictors of
HF severity on multivariate analyses [59].
Miwa et al. [57] assessed 375 consecutive pa-
tients with dilated cardiomyopathy including ischem-
ic (n = 241) and nonischemic causes (n = 134). HRT
was considered positive when both TO was ≥ 0%
and TS was £ 2.5 ms/R-R interval. The primary
endpoint was defined as cardiac mortality and the
secondary endpoint as occurrence of hemodynami-
cally stable sustained ventricular tachyarrhythmias.
HRT positivity was significantly associated in both
the ischemic and NIDCM patients with both the pri-
mary endpoint and with combined endpoints [57].
Klingenheben et al. [60] evaluated the predic-
tive value of heart rate turbulence with those of
conventional autonomic risk markers for ventricu-
lar tachyarrhythmic events in 114 patients with
NIDCM. Determinate test results were obtained for
heart rate variability in 98%, for BRS in 90%, and
for heart rate turbulence in 75% of patients. Dur-
ing a follow-up of 22 ± 17 months, an end point
event occurred in 15 patients. BRS was found as
a significant predictor of arrhythmic events both on
univariate and multivariate analysis, whereas HRT
did not yield predictive power in these patients.
Baroreceptor sensitivity testing
Baroreceptor sensitivity is a marker of the ca-
pability of reflexes to increase vagal activity and to
decrease sympathetic activity in response to a sud-
den increase in blood pressure. Phenylephrine (2–
–4 mg/kg) is given intravenously by at least three
bolus injections at intervals of 10 minutes to raise
systolic arterial pressure by 15–40 mm Hg.
Mortara et al. [61] focused on the prognostic
value of BRS testing in 282 patients with HF. They
found a significantly higher mortality among pa-
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tients with greatly reduced baroreflex sensitivity
(< 1.3 ms/mm Hg) compared to those with more
preserved reflex activity. However, half of the pa-
tients in that study were suffering from CAD. In the
Marburg Cardiomyopathy Study, Grimm et al. [24]
reported no correlation between BRS results and
sudden death during the follow-up.
The evidence suggests that BRS is not a reli-
able risk stratification method for SCD in NIDCM,
and may not have additional benefit over other
markers of autonomic tone, such as HRV. In the
ACC/AHA/ESC 2006 Guidelines for Management
of Patients with Ventricular Arrhythmias and the
Prevention of Sudden Cardiac Death, the use of
ECG techniques (SAECG, HRV, HRT and BRS) is
recommended as possibly useful to improve the
diagnosis and risk stratification of patients with
ventricular arrhythmias or who are at risk of devel-
oping life-threatening ventricular arrhythmias
(Class II, Level of Evidence: B) [5].
Heart rate recovery and
recovery ventricular ectopy
Heart rate recovery after graded exercise is
one of the most commonly used techniques which
reflect autonomic activity. Immediately after grad-
ed exercise, heart rate normally falls in a biphasic
manner, with an initial rapid decline occurring dur-
ing the first 30–60 s of recovery [62, 63]. Imai et al.
[64] demonstrated that this initial steep descent is
marked in athletes and attenuated in patients with
HF and that it can be eliminated by administra-
tion of atropine. Thus, parasympathetic reactiva-
tion probably plays a major role in regulating heart
rate recovery. Because impaired parasympathet-
ic tone correlates with increased risk of death, it
was hypothesized that an attenuated heart rate
recovery would similarly predict an increased risk
of death [4].
Severe ventricular ectopy during recovery af-
ter exercise is predictive of increased mortality in
patients with severe HF and can be used as a prognos-
tic indicator of adverse outcomes in HF cohorts [4].
O’Neill et al. [65] assessed 2,123 (49.1% NIDCM)
consecutive patients with left ventricular systolic
ejection fraction £ 35% who were referred for
symptom-limited metabolic treadmill exercise test-
ing. Severe ventricular ectopy was defined as the
presence of ventricular triplets, sustained or NSVT,
ventricular flutter, polymorphic VT, or VF. The
primary end point was all-cause mortality, with cen-
soring for interval cardiac transplantation. Severe
ventricular ectopy during recovery was associated
with an increased risk of death.  After adjustment
for ventricular ectopy at rest and during exercise,
peak oxygen uptake, and other potential confound-
ers, severe ventricular ectopy during recovery re-
mained an independent predictor of death.
Fragmented QRS
Fragmented QRS (fQRS) is defined on the rou-
tine 12-lead ECG and includes various morpholo-
gies of the QRS wave with or without a Q wave.
Fragmented QRS includes the presence of an addi-
tional R wave (R’) or notching in the nadir of the
R wave or the S wave, or the presence of >1 R’ (frag-
mentation) in two contiguous leads, corresponding
to a major coronary artery territory [66]. Typical
BBB pattern (QRS > 120 ms) and incomplete right
BBB were excluded from the definition of fQRS.
The mechanism of fragmentation in the QRS com-
plex on the surface 12-lead ECG has been explained
by inhomogeneous activation of the ventricles be-
cause of myocardial scar and/or ischemia. The
amount, distribution, and pattern of scar depends
on the disease states. Scars in patients with nonis-
chemic cardiomyopathy are patchy and mid-myocar-
dial or subepicardial. Therefore, different morpho-
logies of fQRS are caused by shifting of the QRS
vector during depolarization in and around the ar-
eas of scarred or ischemic myocardium, depending
on their extent and location in the ventricles [66].
Michael et al. [67] studied arrhythmic events
and all-cause mortality in 105 patients with
NIDCM who received an ICD for primary and se-
condary prophylaxis. The combined endpoint of ICD
therapy and mortality was also significantly higher
in the fQRS group as compared to the non-fQRS
group (70% vs 17.6%). Mortality was 24% in the
fQRS group and 14% in the non-fQRS group. Event-
free survival was significantly decreased in the
fQRS group versus the non-fQRS group.
Fragmented QRS on 12-lead ECG might be
a predictor of arrhythmic events in patients with
NIDCM. Note that fQRS is a nonspecific finding and
should only be interpreted in the presence of perti-
nent clinical evidence.
Cardiac magnetic resonance imaging
Cardiac magnetic resonance (CMR) imaging is
a powerful tool to assess morphology and myocar-
dial function, as well as changes in tissue structure.
Myocardial damage, viability, and scarring have
been frequently studied in patients with post-myo-
cardial infarction using pathological late uptake of
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extracellular MR contrast media by the ventricular
myocardium (LGE, late gadolinium enhancement)
[68]. Wu et al. [69] examined NIDCM patients with
LVEF £ 35% who underwent CMR before place-
ment of an ICD for primary prevention of sudden
cardiac death. After adjustment for LV volume in-
dex and functional class, patients with LGE had an
eight times greater risk of experiencing the prima-
ry outcome. Hombach et al. [70] assessed 141 pa-
tients with NIDCM. LGE was detected in 36 pa-
tients (26%). The presence of LGE, QRS > 110 ms
and diabetes mellitus were found to be significant
parameters for a worse outcome.
Nonlinear dynamics
Clinicians and basic investigators are increas-
ingly aware of the remarkable interest in nonlinear
dynamics (Chaos Theory). In linear systems, the
magnitude of the output (y) is controlled by that of
the input (x) according to simple equations in the
familiar form y = mx + b [71, 72]. Two central fea-
tures of linear systems are proportionality and su-
perposition. Proportionality means that the output
bears a straight-line relationship to the input. Su-
perposition refers to the fact that the behaviour of
linear systems composed of multiple components
can be fully understood. In contrast, even simple
nonlinear systems violate the principles of propor-
tionality and superposition. Nonlinear dynamics
include nonlinearity, fractals, periodic oscillations,
bifurcations, complexity and chaos [71, 72].
Researchers and clinicians should recognize
that arrhythmic cardiac death is a nonlinear and
heterogeneous phenomenon. The transitions be-
tween rhythms capable of sustaining life and those
that lead to death occur via a variety of different
scenarios that are amenable to analysis [71, 72].
Although for now it will be necessary to rely on
criteria for risk stratification based on large clinical
studies, in the future, individualized analyses that
combine traditional clinical measures of cardiac risk
with genetic and mathematical analyses that offer
insight into the pathophysiology of individual pa-
tients should provide improved methods of risk
stratification [72].
Conclusions
In conclusion, it appears that a NIDCM patient
has a less certain clinical course in terms of SCD
compared to similar patients with ischemic cardio-
myopathy. Current indications for ICD implanta-
tion envisage large numbers of patients at risk of
SCD. Due to the substantial costs of these devices,
it would not be feasible to place them in all patients
with NIDCM. Most of the current trials of risk strat-
ification for patients with NIDCM are underpow-
ered and non-randomized. Further studies that de-
fine the precise role of various risk stratification
modalities are needed.
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